<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Artherholt, Samantha</style></author><author><style face="normal" font="default" size="100%">Smith, Amanda E</style></author><author><style face="normal" font="default" size="100%">Acosta Garcia, M J</style></author><author><style face="normal" font="default" size="100%">Bombardier, Charles H</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">inMotion: A phone-based randomized controlled trial to increase physical activity and improve mood</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of MS Care</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://ijmsc.org/doi/pdf/10.7224/1537-2073-14.S2.1</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">25</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;Background: Major depressive disorder (&lt;/span&gt;MDD&lt;span style=&quot;line-height: 1.5;&quot;&gt;) is a common secondary condition in individuals with multiple sclerosis&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;(MS), with a lifetime prevalence estimated to be near 50%.&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;MDD is highly disabling in this population, contributing to&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;time lost from work, low quality of life, and poor health.&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;Commonly used treatments for &lt;/span&gt;MDD&lt;span style=&quot;line-height: 1.5;&quot;&gt; are not effective for&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;many with MS, and there are often major barriers to treatment. Numerous studies have shown that inactivity is a risk&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;factor for &lt;/span&gt;MDD&lt;span style=&quot;line-height: 1.5;&quot;&gt;, while increased activity is associated with&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;reduced risk of &lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;MDD&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;. We have previously shown that physical activity has promise as a treatment for &lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;MDD&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;, especially&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;for people with disabilities such as MS who may be inactive.&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;The current study extends this model to people aging with&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;MS and/or with limited mobility, including wheelchair users.&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;Objectives: The &lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;inMotion&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt; Study is an ongoing randomized&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;controlled trial (&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;RCT&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;) for people aged &lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;&amp;ge;45&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt; with depressive&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;symptoms (10 or higher on the &lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;PHQ-9&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;). The objectives are&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;to increase physical activity and improve mood. Methods:&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;Participation is entirely by phone. Participants in the treatment condition receive seven motivational interviewing (MI)&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;sessions over 12 weeks in which they review exercise history,&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;goals, benefits, and barriers with a study counselor. Half of&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;the intervention group receives two booster calls during the&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;maintenance phase of the study (weeks 13&amp;ndash;24). Participants&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;in the control condition receive a single &lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;psychoeducational&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;session at week 0. All participants are mailed an MS exercise DVD. Physical activity is recorded via &lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;actigraphy&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt; at&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;baseline, 12 weeks, and 24 weeks. An independent examiner assesses outcomes in both groups at 12 and 24 weeks. &lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;Results: To date, 219 potential participants with MS have&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;been screened, with 52 enrolled (24%), 6 refused (3%), and&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;161 ineligible (74%). Ineligibility has been due primarily to&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;lack of depressive symptoms (N = 98, 61%). Conclusions:&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;A phone-based intervention to increase physical activity and&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;improve depression in people with MS is feasible, although&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;recruitment challenges have been significant. Results of&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;this RCT will determine the efficacy of this phone-based MI&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;approach to improving mood in people with MS, and will&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: 1.5;&quot;&gt;explore potential mediators such as fatigue, pain, and general health.&lt;/span&gt;&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">S2</style></issue></record></records></xml>